YELLOWYELLOW
FEVERFEVER
SUJATA MOHAPATRA.SUJATA MOHAPATRA.
OUTLINEOUTLINE
 IntroductionIntroduction
 Disease BackgroundDisease Background
 DistributionDistribution
 EpidemiologyEpidemiology
 TransmissionTransmission
 Diagnosis & managementDiagnosis & management
 Prevention and ControlPrevention and Control
 Actions to TakeActions to Take
Disease BackgroundDisease Background
 First account ofFirst account of
sickness diagnosed assickness diagnosed as
YF occurred in 1648.YF occurred in 1648.
 Causative agent:Causative agent:
genus Flavivirus.genus Flavivirus.
 Vector: Aedes aegyptiVector: Aedes aegypti
(mosquito).(mosquito).
 Nonhuman primatesNonhuman primates
maintain disease.maintain disease.
Global DistributionGlobal Distribution
 In 45 countries ofIn 45 countries of
Africa & LatinAfrica & Latin
America.America.
 More than 900 millionMore than 900 million
people are at risk.people are at risk.
 200,000 cases &200,000 cases &
30,000 deaths30,000 deaths
worldwide each year.worldwide each year.
EPIDEMIOLOGYEPIDEMIOLOGY
Flavivirus FibricusFlavivirus Fibricus
ManMan
Forest(>24Forest(>2400
))
YELLOW
FEVER
AgentAgent
 Flavivirus FibricusFlavivirus Fibricus
 Group B ArbovirusGroup B Arbovirus
Reservoir & VectorReservoir & Vector
 MonkeyMonkey
 MosquitoMosquito
Host FactorHost Factor
 All ages & both sexesAll ages & both sexes
 Persons in contact withPersons in contact with
forests.forests.
 Wood cutters, Hunters.Wood cutters, Hunters.
 Immunity-Immunity- One attack ofOne attack of
yellow fever givesyellow fever gives
lifelonglifelong immunity.immunity.
The SEVIR ModelThe SEVIR Model
Humans can be in one of five categories at a time.
*Virus incubating*Virus incubating
**Contagious**Contagious
***Includes: survivors, victims, Immune***Includes: survivors, victims, Immune
Susceptible Exposed* Infective** Recovered***
Vaccinated
Environmental FactorEnvironmental Factor
 ClimateClimate
 Tropical with a relativeTropical with a relative
humidity.humidity.
 Endemic presence ofEndemic presence of
disease in the jungle.disease in the jungle.
 Social FactorsSocial Factors
 Urbanization,Urbanization,
 More Populated,More Populated,
 Forest.Forest.
INCUBATION PERIODINCUBATION PERIOD –– 3-6 days3-6 days
PERIOD OF COMMUNICABILITYPERIOD OF COMMUNICABILITY -- Blood ofBlood of
patients is infective during the first 3-4days.patients is infective during the first 3-4days.
Cycles of YFCycles of YF
TransmissionTransmission
MOSQUITO
MONKE
Y
HUMAN,
MONKE
Y
MOSQUIT
O
HUMAN HUMAN
MOSQUIT
O
MOSQUITO
MOSQUIT
O
MOSQUITO
Jungle Village City
www.who.int
Clinical featuresClinical features
Diagnosis &Diagnosis &
ManagementManagement
 Blood studiesBlood studies
 Supportive TreatmentSupportive Treatment
 IV FluidsIV Fluids
 AntipyreticsAntipyretics
 AntibioticsAntibiotics
 Use of Mosquito-net orUse of Mosquito-net or
mosquito repellents.mosquito repellents.
Prevention & ControlPrevention & Control
 17D17D Vaccine,Vaccine,
 SubcutaneouslySubcutaneously 0.5ml0.5ml,,
 Immunity begins to appear on theImmunity begins to appear on the77thth
day & lasts for more thanday & lasts for more than 35 years35 years..
 International Certificates.International Certificates.
Yellow fever
Yellow fever

Yellow fever

  • 3.
  • 4.
    OUTLINEOUTLINE  IntroductionIntroduction  DiseaseBackgroundDisease Background  DistributionDistribution  EpidemiologyEpidemiology  TransmissionTransmission  Diagnosis & managementDiagnosis & management  Prevention and ControlPrevention and Control  Actions to TakeActions to Take
  • 5.
    Disease BackgroundDisease Background First account ofFirst account of sickness diagnosed assickness diagnosed as YF occurred in 1648.YF occurred in 1648.  Causative agent:Causative agent: genus Flavivirus.genus Flavivirus.  Vector: Aedes aegyptiVector: Aedes aegypti (mosquito).(mosquito).  Nonhuman primatesNonhuman primates maintain disease.maintain disease.
  • 6.
    Global DistributionGlobal Distribution In 45 countries ofIn 45 countries of Africa & LatinAfrica & Latin America.America.  More than 900 millionMore than 900 million people are at risk.people are at risk.  200,000 cases &200,000 cases & 30,000 deaths30,000 deaths worldwide each year.worldwide each year.
  • 7.
  • 8.
    AgentAgent  Flavivirus FibricusFlavivirusFibricus  Group B ArbovirusGroup B Arbovirus
  • 10.
    Reservoir & VectorReservoir& Vector  MonkeyMonkey  MosquitoMosquito
  • 11.
    Host FactorHost Factor All ages & both sexesAll ages & both sexes  Persons in contact withPersons in contact with forests.forests.  Wood cutters, Hunters.Wood cutters, Hunters.  Immunity-Immunity- One attack ofOne attack of yellow fever givesyellow fever gives lifelonglifelong immunity.immunity.
  • 12.
    The SEVIR ModelTheSEVIR Model Humans can be in one of five categories at a time. *Virus incubating*Virus incubating **Contagious**Contagious ***Includes: survivors, victims, Immune***Includes: survivors, victims, Immune Susceptible Exposed* Infective** Recovered*** Vaccinated
  • 13.
    Environmental FactorEnvironmental Factor ClimateClimate  Tropical with a relativeTropical with a relative humidity.humidity.  Endemic presence ofEndemic presence of disease in the jungle.disease in the jungle.  Social FactorsSocial Factors  Urbanization,Urbanization,  More Populated,More Populated,  Forest.Forest.
  • 14.
    INCUBATION PERIODINCUBATION PERIOD–– 3-6 days3-6 days PERIOD OF COMMUNICABILITYPERIOD OF COMMUNICABILITY -- Blood ofBlood of patients is infective during the first 3-4days.patients is infective during the first 3-4days.
  • 15.
    Cycles of YFCyclesof YF TransmissionTransmission MOSQUITO MONKE Y HUMAN, MONKE Y MOSQUIT O HUMAN HUMAN MOSQUIT O MOSQUITO MOSQUIT O MOSQUITO Jungle Village City www.who.int
  • 16.
  • 17.
    Diagnosis &Diagnosis & ManagementManagement Blood studiesBlood studies  Supportive TreatmentSupportive Treatment  IV FluidsIV Fluids  AntipyreticsAntipyretics  AntibioticsAntibiotics  Use of Mosquito-net orUse of Mosquito-net or mosquito repellents.mosquito repellents.
  • 18.
    Prevention & ControlPrevention& Control  17D17D Vaccine,Vaccine,  SubcutaneouslySubcutaneously 0.5ml0.5ml,,  Immunity begins to appear on theImmunity begins to appear on the77thth day & lasts for more thanday & lasts for more than 35 years35 years..  International Certificates.International Certificates.